EYPT — Expiration of Patent US10799642 related to DEXYCU KIT
May 11, 2032, 12:00:00 AM UTC
Summary
The patent US10799642, associated with the DEXYCU KIT, is set to expire on May 11, 2032. This patent, attributed to Icon Bioscience Inc and EyePoint Pharmaceuticals Inc, covers devices that facilitate the loading and dispensing of precise small doses of fluid from standard injection syringes. The expiration could potentially impact the product's market exclusivity and open opportunities for generic alternatives, which may affect the financial landscape for both companies involved.
Company
EYEPOINT PHARMACEUTICALS INC (EYPT)NASDAQ — Healthcare: Manufacturing, Biotechnology: Laboratory Analytical Instruments
eyepointpharma.comSimilar Events
Expiration of Patent US11097061 for DEXYCU KIT
Patent US11097061 for the DEXYCU KIT, developed by Icon Bioscience Inc and EyePoint Pharmaceuticals Inc, is set to expire on June 23, 2039. DEXYCU is a kit designed to facilitate the precise loading and delivery of small volume doses of medication, particularly at treatment sites, such as the conclusion of ocular surgeries. The expiration of this patent could potentially lead to increased competition in the market, as generics may emerge, impacting the financial landscape for the companies involved.
PatentPatent US10022502 Expiration Related to DEXYCU KIT
The patent US10022502, assigned to Icon Bioscience Inc and EyetPoint Pharmaceuticals Inc, is set to expire on June 22, 2034, relating to the DEXYCU KIT. This patent covers devices that facilitate the accurate loading and dispensing of predefined doses of fluid from injection syringes, which is essential to the functionality of the DEXYCU KIT, a product designed for sustained release of a corticosteroid in the eye. The expiration may allow for increased competition in the market, impacting EyetPoint Pharmaceuticals' sales and market position.
Patent ExpirationPatent US10028965 Expires for DEXYCU KIT
Patent US10028965 for the DEXYCU KIT, developed by Icon Bioscience Inc and Eyepoint Pharmaceuticals Inc, is set to expire on May 23, 2034. The patent covers a short-term, sustained-release liquid formulation of dexamethasone, designed to provide anti-inflammatory therapy following cataract surgery through a single administration into the anterior chamber of the eye. This expiration could potentially allow for generic competition, impacting market exclusivity and associated revenues for the companies involved.
Patent ExpirationExpiration of Patent US8871273 related to DEXILANT
Patent US8871273 for DEXILANT, assigned to Takeda Pharmaceutical Co Ltd and TAKEDA PHARMACEUTICALS USA INC, will expire on January 11, 2028. This patent is significant as it pertains to a production process that enhances the consistency of the elution profile of DEXILANT, which is used to treat gastroesophageal reflux disease. The expiration may lead to increased competition from generic alternatives, potentially impacting Takeda's revenue from this product.
Patent Expiration